Quantcast

Posts related to ‘Healthcare’

biotech

Another Major MS Approval Keeps Driving Biogen Idec

Shares of Biogen Idec Inc. (NASDAQ: BIIB) did not just do well on Wednesday. The stock hit an all-time high. News hit late in the day that the U.S. Food ...
Read Full Story »
biotech

Aastrom Implosion Could Have Been Even Worse

Aastrom Biosciences Inc. (NASDAQ: ASTM) has just joined in on the long list of biotech implosions. Perhaps the only thing that is so surprising after the fact, with a 35% ...
Read Full Story »
Stock Split Image

Chelsea Therapeutics Rally — Speculation or Desperation?

Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is rallying on Wednesday after a report in Seeking Alpha called its Northera, a treatment for symptomatic neurogenic hypotension in Parkinson's patients, a shoe-in for approval, ...
Read Full Story »
76764023

Merrill Lynch Picks Diabetes Drug Makers as Real Winners (MRK, BMY, LLY, NOV, MNKD, BAC)

According to the Center for Disease Control (CDC), more than one-third (35.7%) of all adults in the United States are obese. Obesity-related medical conditions include heart attack, stroke, type-2 diabetes ...
Read Full Story »
biotech

ZIOPHARM Joins Biotech Implosion Watch After Sarcoma Failure

ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) is on implosion watch. The small-cap biotech is indicated to be way down on a major disappointment on its Phase 3 trial of palifosfamide for ...
Read Full Story »
biotech

The Risk-Reward Case for Sarepta — Stock Going to $19 or $47 by Mid-May

Sarepta Therapeutics Inc. (NASDAQ: SRPT) should have received a huge boost from "The Barron's Effect" on Monday. The financial publication, which historically has been referred to as the "Investor's Weekly Bible ...
Read Full Story »
Cloud computing

Model N Sets Up for Strong IPO Debut

Investors always seem to be on the lookout for initial public offerings. The newest IPO coming to market is Model N Inc. (NASDAQ: MODN), with its revenue management software for ...
Read Full Story »
Stock Split Image

The American Retirement Asset Crisis Is Upon Us

A fresh report from the Employee Benefit Research Institute is signaling that most Americans are going to be retiring with nowhere close to having enough assets and savings for retirement. ...
Read Full Story »
Pills

Omthera Pharmaceuticals Files for IPO

Omthera Pharmaceuticals has joined the wave of companies wanting to come public. Omthera is a clinical stage biotech and will trade under the ticker OMTH on Nasdaq after its initial ...
Read Full Story »
Bull and Bear

13 Must-Read Weekend Stock Stories for Monday

It may be the weekend, and the DJIA hit a new high this last week, but there is no such thing as any rest for the wicked. 24/7 Wall St. ...
Read Full Story »
Money, US, $100 bills

Pharmacyclics Does Smart and Opportunistic Capital Raise After Huge Run Up

Pharmacyclics Inc. (NASDAQ: PCYC) has had a monster stock performance, with gains of much more than 200% over the past year. Now the company is doing what some shareholders will ...
Read Full Story »
biotech

Nymox Tries for Recovery on Safety Profile of NX-1207 for Prostate Cancer

Nymox Pharmaceutical Corp. (NASDAQ: NYMX) took a mystery beating last Friday, to the point that a single stock circuit breaker was triggered for a halt. The company said that it had no ...
Read Full Story »
rumors

Pharma Merger/Buyout Hunt Continues in Biotech, Valuations Under Focus

The hunt by Big Pharma stocks for smaller drug companies and biotech stocks continues. A report citing "sources" from Dow Jones News has signaled that Bristol-Myers Squibb (NYSE: BMY) has ...
Read Full Story »
biotech

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

24/7 Wall St. is taking a daily aim at the world exchange-traded funds (ETFs). Many are great, and many are actively traded and truly represent what investors are trying to ...
Read Full Story »
biotech

ETF Folly: Biotech ETFs, Nothing but Confusion

24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector performed ...
Read Full Story »